Literature DB >> 21236688

Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.

Alessandra Gaeta1, Francisco Molina-Holgado, Xiao L Kong, Sarah Salvage, Sarah Fakih, Paul T Francis, Robert J Williams, Robert C Hider.   

Abstract

A novel class of 2-amido-3-hydroxypyridin-4-one iron chelators is described. These compounds have been designed to behave as suitable molecular probes which will improve our knowledge of the role of iron in neurodegenerative conditions. Neurodegenerative disorders, such as Alzheimer's disease (AD) and Parkinson disease (PD), can be considered as diverse pathological conditions sharing critical metabolic processes such as protein aggregation and oxidative stress. Interestingly, both these metabolic alterations seem to be associated with the involvement of metal ions, including iron. Iron chelation is therefore a potential therapeutic approach. The physico-chemical (pK(a), pFe(3+) and logP) and biological properties (inhibition of iron-containing enzymes) of these chelators have been investigated in order to obtain a suitable profile for the treatment of neurodegenerative conditions. Studies with neuronal cell cultures confirm that the new iron chelators are neuroprotective against β-amyloid-induced toxicity.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21236688     DOI: 10.1016/j.bmc.2010.12.007

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  In silico and in vitro studies to elucidate the role of Cu2+ and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process.

Authors:  Maricarmen Hernández-Rodríguez; José Correa-Basurto; Claudia G Benitez-Cardoza; Aldo Arturo Resendiz-Albor; Martha C Rosales-Hernández
Journal:  Protein Sci       Date:  2013-08-19       Impact factor: 6.725

2.  Aroylhydrazones constitute a promising class of 'metal-protein attenuating compounds' for the treatment of Alzheimer's disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone.

Authors:  Daphne S Cukierman; Elio Accardo; Rosana Garrido Gomes; Anna De Falco; Marco C Miotto; Maria Clara Ramalho Freitas; Mauricio Lanznaster; Claudio O Fernández; Nicolás A Rey
Journal:  J Biol Inorg Chem       Date:  2018-08-25       Impact factor: 3.358

Review 3.  Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives.

Authors:  Ailton Melo; Larissa Monteiro; Rute M F Lima; Diêgo M de Oliveira; Martins D de Cerqueira; Ramon S El-Bachá
Journal:  Oxid Med Cell Longev       Date:  2011-11-24       Impact factor: 6.543

4.  Dual-target anti-Alzheimer's disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity.

Authors:  Zhisheng Mi; Bing Gan; Sihang Yu; Jianan Guo; Changjun Zhang; Xiaoying Jiang; Tao Zhou; Jing Su; Renren Bai; Yuanyuan Xie
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

5.  Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1H)-one iron chelators in an in vitro cell model of Parkinson's disease.

Authors:  Frank W Lewis; Kathleen Bird; Jean-Philippe Navarro; Rawa El Fallah; Jeremy Brandel; Véronique Hubscher-Bruder; Andrew Tsatsanis; James A Duce; David Tétard; Samuel Bourne; Mahmoud Maina; Ilse S Pienaar
Journal:  Dalton Trans       Date:  2022-03-01       Impact factor: 4.390

Review 6.  Iron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease.

Authors:  Andrew Gleason; Ashley I Bush
Journal:  Neurotherapeutics       Date:  2020-10-27       Impact factor: 7.620

Review 7.  The essential elements of Alzheimer's disease.

Authors:  Peng Lei; Scott Ayton; Ashley I Bush
Journal:  J Biol Chem       Date:  2020-11-27       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.